Business Wire

WorldFirst's Enhanced Bank Partnerships and AI Tools Fuel 300% Transaction Growth in Emerging Markets

30.9.2025 14:48:00 CEST | Business Wire | Press Release

Share

WorldFirst, an all-in-one digital cross-border payment and treasury account service for global businesses, announced a 300% surge in emerging markets transaction volume during the first half of 2025. The growth figures were disclosed during WorldFirst's recent Financial Partners Day in London, which was attended by more than 60 representatives from over 30 financial institutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930587669/en/

WorldFirst and its financial partners came together to discuss how to advance collaboration to better serve SMEs at the WorldFirst Financial Partners Day in London.

A key goal of the Eurosystem’s retail payments strategy is to make it easier for businesses in Europe to send and receive payments to and from other countries. Against this backdrop, the event discussed how to leverage bank-fintech collaboration—through interoperability, SME-focused solutions, and digital innovation—to build a more resilient and inclusive financial ecosystem.

Simplifying Global Payments for Growing Businesses

Coco XU, founder of London-based pet supply brand Cococat, saw her eco-friendly cat litter soar into Amazon's top 100 within a year. "As a new brand with global ambition, our biggest challenge was managing multi-currency cash flow and securing efficient fund transfers to the UK," she said.

The turning point came when Cococat discovered WorldFirst. By leveraging WorldFirst’s account service, Cococat reduced transaction costs by 20% compared to traditional methods while cutting settlement time from 5-7 days to near real-time.

The story exemplifies the broader industry transformation. Over 1.2 million merchants worldwide, including Cococat, are using WorldFirst's bank-supported solutions featuring global coverage, secure transactions and operational efficiency. Key offerings include:

  • World Account- A one-stop account for global payments, collections, FX conversion, and treasury management. Merchants can apply online in minutes to pay in 100+ currencies and collect in 20+ currencies to 200+ countries and regions.
  • World Card- The virtual card solution empowers SMEs to streamline secure domestic and cross-border payments with greater financial control. The solution also plans to introduce credit access in the future and has scheduled a full-scale rollout in Europe this year.
  • Value-added services- Competitive wholesale FX rates and forward contracts help SMEs reduce costs and hedge against currency risk, with a clear pathway to future advanced cash management solutions.

"The power of fintech-bank collaboration lies in building a more robust and inclusive financial ecosystem," noted Clara SHI, CEO of WorldFirst. "This synergy enables us to deliver solutions with global coverage, efficiency, and security to SMEs engaged in cross-border commerce. In turn, it provides our financial partners with a strategic gateway to the vibrant—and often hard-to-reach—SME economy."

WorldFirst’s banking network includes eight global systemically important banks, such as J.P. Morgan, Standard Chartered, Barclays, HSBC, Citibank and others. In Europe, BNP Paribas stands as one of its key strategic partners.

Pierre Fersztand, Global Head of Cash Management, Trade Solutions & Factoring at BNP Paribas, commented on the partnership: "Today’s clients expect seamless digital experiences supported by the stability of a global bank. Our collaboration with WorldFirst ensures we remain at the forefront of providing innovative trade finance and cash management services that drive growth and financial inclusion."

What’s next? Extending the technology and innovation to the industry

Banks and fintechs are making significant technological strides to bridge the gap between the needs of the global economy and the capabilities of today's cross-border payment systems. As part of this effort, WorldFirst is launching a series of AI-driven initiatives to enhance security, compliance, and user experience:

AI-driven risk management- WorldFirst enhances its fraud detection capabilities by integrating advanced AI and machine learning algorithms. This enables real-time transaction screening, maintains a sub-0.01% fraud rate, and streamlines compliance processes.

AI-Guided Cross-Border Support- WorldFirst’s intelligent assistant Anthea, provides 24/7 multilingual support—helping sellers overcome cross-cultural barriers, language gaps, and local payment preferences.

"At WorldFirst, we see AI as the core driver for the next generation of cross-border trade," highlighted Clara. "Our focus is shifting from merely leveraging AI for risk defense to actively deploying it to empower businesses. By simplifying technical complexity, we are democratizing access to the global economy and turning cross-border payments into a streamlined experience for every business."

Mahesh Kini, Global Head of Cash Management, Standard Chartered, said: "We are pleased to see the increased positive impact that our partnership with WorldFirst is making on its clients and the broader ecosystem. This is in line with our efforts to offer seamless and secure last mile digital payment and FX solutions that enable these companies to scale their operations."

Complementing its digital capabilities, WorldFirst is also expanding its physical presence with new offices in Kuala Lumpur, Mexico, the UAE, and Saudi Arabia—strengthening its local support network across key markets.

This approach resonates deeply with clients. As the founder of Cococat Coco Xu noted: "Another key deciding factor was WorldFirst’s physical presence. Knowing they have an office here in London is incredibly reassuring. Whenever we have a question, we can talk to a real person who understands our local context. It truly feels like a partnership."

About WorldFirst

WorldFirst offers cross-border payments and treasury services through its global business account, empowering growth for SMEs in e-commerce, trade, and the broad platform economy. WorldFirst simplifies key financial operations, including international payments, collections, currency conversions, and treasury management, all in a one-stop account. Leveraging the technological strengths, WorldFirst delivers industry-leading transaction security and reliability. WorldFirst has supported over 1.2 million customers, enabling payments in 100+ currencies across more than 210 countries and regions. Learn more about WorldFirst at https://www.worldfirst.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930587669/en/

Contacts

Chloe ZHU
jingchong.zhu@ant-intl.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye